• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

DBC1 是增强子表观遗传 writers KMT2D 和 p300 的关键正调控因子。

DBC1 is a key positive regulator of enhancer epigenomic writers KMT2D and p300.

机构信息

Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, 06351, South Korea.

Research Institute for Future Medicine, Samsung Medical Center, Seoul, 06351, South Korea.

出版信息

Nucleic Acids Res. 2022 Aug 12;50(14):7873-7888. doi: 10.1093/nar/gkac585.

DOI:10.1093/nar/gkac585
PMID:35801925
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9371912/
Abstract

Histone modification is a key epigenetic mechanism for regulation of chromatin dynamics and gene expression. Deleted in breast cancer 1 (DBC1) has been shown to act as a negative regulator of epigenetic modifiers and as a co-activator for nuclear receptors and other transcription factors. However, little is known about the role of DBC1 in the regulation of histone modifications and chromatin landscapes. Here, we analyzed genome-wide profiles of active enhancer and promoter marks in colorectal cancer cells and report DBC1 as a critical positive regulator of histone epigenetic writers KMT2D (H3K4 methyltransferase) and p300 (histone acetyltransferase). DBC1 is required for establishing the landscape of active enhancers, for genome-wide chromatin binding and enhancer recruitment of KMT2D and p300, and for gene activation involved in colorectal cancer progression. DBC1 interacts directly with KMT2D and p300, and enhances KMT2D-mediated histone H3K4 methylation (H3K4me1/2/3) and p300-mediated H3 acetylation. Importantly, DBC1 contributes to super-enhancer formation and function by facilitating the recruitment of KMT2D and p300 and by enhancing their functional interaction and cooperative cross-talk. Our results highlight the critical role of DBC1 as a key positive regulator of KMT2D and p300, and provide insights into regulatory mechanisms underlying the interplay between the enhancer epigenomic writers in enhancer activation.

摘要

组蛋白修饰是调节染色质动态和基因表达的关键表观遗传机制。乳腺癌缺失基因 1(DBC1)已被证明作为表观遗传修饰物的负调节剂以及核受体和其他转录因子的共激活剂发挥作用。然而,关于 DBC1 在组蛋白修饰和染色质景观调节中的作用知之甚少。在这里,我们分析了结直肠癌细胞中活性增强子和启动子标记的全基因组图谱,并报告 DBC1 是组蛋白表观遗传作家 KMT2D(H3K4 甲基转移酶)和 p300(组蛋白乙酰转移酶)的关键正调控因子。DBC1 对于建立活性增强子景观、KMT2D 和 p300 的全基因组染色质结合和增强子募集以及涉及结直肠癌细胞进展的基因激活是必需的。DBC1 与 KMT2D 和 p300 直接相互作用,并增强 KMT2D 介导的组蛋白 H3K4 甲基化(H3K4me1/2/3)和 p300 介导的 H3 乙酰化。重要的是,DBC1 通过促进 KMT2D 和 p300 的募集以及增强它们的功能相互作用和协同交叉对话,有助于超级增强子的形成和功能。我们的研究结果强调了 DBC1 作为 KMT2D 和 p300 的关键正调控因子的关键作用,并为增强子激活中增强子表观遗传作家之间相互作用的调控机制提供了新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ea/9371912/aedef8b9b563/gkac585fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ea/9371912/2ffb682009a0/gkac585fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ea/9371912/b6e3a214b85a/gkac585fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ea/9371912/70188a0784bd/gkac585fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ea/9371912/964ac8a282ee/gkac585fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ea/9371912/5b4281bdecfc/gkac585fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ea/9371912/3004a93a9972/gkac585fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ea/9371912/aedef8b9b563/gkac585fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ea/9371912/2ffb682009a0/gkac585fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ea/9371912/b6e3a214b85a/gkac585fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ea/9371912/70188a0784bd/gkac585fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ea/9371912/964ac8a282ee/gkac585fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ea/9371912/5b4281bdecfc/gkac585fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ea/9371912/3004a93a9972/gkac585fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15ea/9371912/aedef8b9b563/gkac585fig7.jpg

相似文献

1
DBC1 is a key positive regulator of enhancer epigenomic writers KMT2D and p300.DBC1 是增强子表观遗传 writers KMT2D 和 p300 的关键正调控因子。
Nucleic Acids Res. 2022 Aug 12;50(14):7873-7888. doi: 10.1093/nar/gkac585.
2
A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription.一个UTX-MLL4-p300转录调控网络协同塑造活性增强子景观以引发转录。
Mol Cell. 2017 Jul 20;67(2):308-321.e6. doi: 10.1016/j.molcel.2017.06.028.
3
Enhancer priming by H3K4 methyltransferase MLL4 controls cell fate transition.由H3K4甲基转移酶MLL4介导的增强子预激发控制细胞命运转变。
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11871-11876. doi: 10.1073/pnas.1606857113. Epub 2016 Oct 3.
4
Mutant p53 regulates enhancer-associated H3K4 monomethylation through interactions with the methyltransferase MLL4.突变型 p53 通过与甲基转移酶 MLL4 的相互作用调节增强子相关的 H3K4 单甲基化。
J Biol Chem. 2018 Aug 24;293(34):13234-13246. doi: 10.1074/jbc.RA118.003387. Epub 2018 Jun 28.
5
KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc.KMT2D 通过 H3K4me1 募集 YBX1,通过表观遗传激活 c-Myc 促进三阴性乳腺癌进展。
Clin Transl Med. 2024 Jul;14(7):e1753. doi: 10.1002/ctm2.1753.
6
The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape.MLL3/4 组蛋白 H3K4 甲基转移酶复合物在建立活跃的增强子景观中的作用。
Biochem Soc Trans. 2021 Jun 30;49(3):1041-1054. doi: 10.1042/BST20191164.
7
Histone H3 lysine 4 methyltransferase KMT2D.组蛋白H3赖氨酸4甲基转移酶KMT2D
Gene. 2017 Sep 5;627:337-342. doi: 10.1016/j.gene.2017.06.056. Epub 2017 Jun 29.
8
H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation.H3K4单甲基化和二甲基化转移酶MLL4是细胞分化过程中增强子激活所必需的。
Elife. 2013 Dec 24;2:e01503. doi: 10.7554/eLife.01503.
9
MLL3/MLL4 are required for CBP/p300 binding on enhancers and super-enhancer formation in brown adipogenesis.在棕色脂肪生成过程中,MLL3/MLL4是CBP/p300结合到增强子以及形成超级增强子所必需的。
Nucleic Acids Res. 2017 Jun 20;45(11):6388-6403. doi: 10.1093/nar/gkx234.
10
In Vivo Dissection of Chamber-Selective Enhancers Reveals Estrogen-Related Receptor as a Regulator of Ventricular Cardiomyocyte Identity.在体解析腔选择性增强子揭示了雌激素相关受体是心室心肌细胞特征的调节因子。
Circulation. 2023 Mar 14;147(11):881-896. doi: 10.1161/CIRCULATIONAHA.122.061955. Epub 2023 Jan 27.

引用本文的文献

1
Prognostic and clinicopathological value of dbc1 expression in human cancers: a systematic review and meta-analysis.DBC1表达在人类癌症中的预后及临床病理价值:一项系统评价与Meta分析
Front Oncol. 2025 Jul 7;15:1584622. doi: 10.3389/fonc.2025.1584622. eCollection 2025.
2
P300-dependent acetylation of the FOXQ1 complex activates super-enhancers to promote colorectal cancer proliferation and metastasis.FOXQ1复合物的P300依赖性乙酰化激活超级增强子,以促进结直肠癌的增殖和转移。
Commun Biol. 2025 Jul 7;8(1):1016. doi: 10.1038/s42003-025-08430-z.
3
Multifaceted roles of CCAR family proteins in the DNA damage response and cancer.

本文引用的文献

1
Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance.超级增强子:癌症化疗耐药性中表观遗传修饰物的新前沿。
J Exp Clin Cancer Res. 2021 May 19;40(1):174. doi: 10.1186/s13046-021-01974-y.
2
The language of chromatin modification in human cancers.人类癌症中染色质修饰的语言。
Nat Rev Cancer. 2021 Jul;21(7):413-430. doi: 10.1038/s41568-021-00357-x. Epub 2021 May 17.
3
CCAR1 and CCAR2 as gene chameleons with antagonistic duality: Preclinical, human translational, and mechanistic basis.CCAR1 和 CCAR2 作为具有拮抗双重性的基因变色龙:临床前、人体转化和机制基础。
CCAR 家族蛋白在 DNA 损伤反应和癌症中的多方面作用。
Exp Mol Med. 2024 Feb;56(1):59-65. doi: 10.1038/s12276-023-01139-1. Epub 2024 Jan 4.
4
Mechanistic insights into the dual role of CCAR2/DBC1 in cancer.深入了解 CCAR2/DBC1 在癌症中的双重作用的机制见解。
Exp Mol Med. 2023 Aug;55(8):1691-1701. doi: 10.1038/s12276-023-01058-1. Epub 2023 Aug 1.
5
The Transition from Cancer "omics" to "epi-omics" through Next- and Third-Generation Sequencing.通过下一代测序和第三代测序实现从癌症“组学”到“表观组学”的转变。
Life (Basel). 2022 Dec 2;12(12):2010. doi: 10.3390/life12122010.
Cancer Sci. 2020 Oct;111(10):3416-3425. doi: 10.1111/cas.14579. Epub 2020 Aug 9.
4
Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.布鲁斯汀通过靶向 HSP90 克服去势抵抗性前列腺癌对激素治疗的耐药性。
Theranostics. 2021 Jan 1;11(2):958-973. doi: 10.7150/thno.51478. eCollection 2021.
5
Proximity labeling in mammalian cells with TurboID and split-TurboID.TurboID 和 split-TurboID 在哺乳动物细胞中的邻近标记。
Nat Protoc. 2020 Dec;15(12):3971-3999. doi: 10.1038/s41596-020-0399-0. Epub 2020 Nov 2.
6
The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2020 update.Galaxy 平台,用于实现可访问、可重现和协作的生物医学分析:2020 年更新。
Nucleic Acids Res. 2020 Jul 2;48(W1):W395-W402. doi: 10.1093/nar/gkaa434.
7
H2B ubiquitylation enhances H3K4 methylation activities of human KMT2 family complexes.H2B 泛素化增强了人 KMT2 家族复合物的 H3K4 甲基化活性。
Nucleic Acids Res. 2020 Jun 4;48(10):5442-5456. doi: 10.1093/nar/gkaa317.
8
Oncogenic seRNA functional activation: a novel mechanism of tumorigenesis.致癌性 seRNA 功能激活:一种新的肿瘤发生机制。
Mol Cancer. 2020 Apr 11;19(1):74. doi: 10.1186/s12943-020-01195-5.
9
Super-enhancer function and its application in cancer targeted therapy.超级增强子功能及其在癌症靶向治疗中的应用。
NPJ Precis Oncol. 2020 Feb 12;4:2. doi: 10.1038/s41698-020-0108-z. eCollection 2020.
10
KMT2C/D COMPASS complex-associated diseases [KCOM-ADs]: an emerging class of congenital regulopathies.KMT2C/D COMPASS复合物相关疾病[KCOM-ADs]:一类新兴的先天性调节异常疾病。
Clin Epigenetics. 2020 Jan 10;12(1):10. doi: 10.1186/s13148-019-0802-2.